CryptiVax-1001 / Epitopea - LARVOL DELTA

OVACT: Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - P1 | N=50 | Recruiting | Sponsor: Epitopea Ltd

New P1 trial • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

Epitopea…announced that it has received approval from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and the Regional Ethics Committee (REC) for its clinical trial application (CTA) for its first-in-human clinical trial (OVACT) of its lead program, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (GlobeNewswire) - "OVACT is a Phase 1/1b dose escalation and expansion trial designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype high-grade serous ovarian cancer patients."

First-in-human • New P1 trial • High Grade Serous Ovarian Cancer

Epitopea Closes USD $31 million Pre-Series A Financing (GlobeNewswire) - "Epitopea...announces the closing of a USD $31 million pre-Series A financing...'This pre-Series A raise provides the necessary finances to accelerate our development campaigns and transition to a clinical-stage company with a focused commitment of delivering our transformational RNA cancer immunotherapy into the clinic in 2026,'..."

Financing • Oncology